Jun Tao

Mr. Jun Tao

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Placenta
Verified
Journal Article
Closed access
JTJun Tao
Jun Tao
LXLin-Zhen Xia
Lin-Zhen Xia
LLLingli Liang
Lingli Liang
YCYanjun Chen
Yanjun Chen
DWDangheng Wei
Dangheng Wei
ZWZuo Wang
Zuo Wang

1 June 2021 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
JZJunfa Zeng
Junfa Zeng
JTJun Tao
Jun Tao
LXLinzhen Xia
Linzhen Xia
ZZZhaolin Zeng
Zhaolin Zeng
JCJiaojiao Chen
Jiaojiao Chen
LLLuShan Liu
LuShan Liu
Atherosclerosis (AS) is a chronic inflammatory disease that involves cell death and endothelial dysfunction. Melatonin is an endocrine hormone with anti-inflammatory and anti-AS effects. However, the underlying molecular mechanisms for the anti-AS effects of melatonin are unknown. A previous study has shown that pyroptosis plays a detrimental role in the development of AS, therefore, this study was designed to investigate the anti-pyroptotic effects and potential mechanisms of melatonin in atherosclerotic endothelium. Our results show that melatonin attenuated the expression of genes related to pyroptosis, including NLRP3, caspase-1, and IL-1β, in human umbilical vein endothelial cells treated with oxidized low-density lipoprotein. Furthermore, melatonin up-regulated the expression of ten-eleven translocation 2 (TET2), inhibited the methylation of ubiquinol-cytochrome c reductase core protein 1 (UQCRC1), and reduced pyroptosis. The up-regulation of UQCRC1 by melatonin improved mitochondrial function, thereby inhibiting oxidative stress and endothelial cell pyroptosis. Collectively, our results indicate that melatonin prevents endothelial cell pyroptosis by up-regulating TET2 to inhibit the methylation of UQCRC1 and improving mitochondrial function.